Abstract
Objective: Current studies have proven that early,organ-confined stages of prostate cancer can be diagnosed through screening based on PSA levels, thus reducing cancer mortality. Here we report about our experience using an innovative one-step test for PSA in capillary blood. Methods: The incubation time for a 50 μl blood sample with the indicator strip is 12 minutes until the qualitative visual results (<4.0 ng/ml or ≥ 4 ng/ml)appear. In cooperation with urologists and accompanied by an extensive information campaign, the one-step test was made available free of charge to all men between the ages of 45 and 75 in all 28 pharmacies of our city (100,000 inhabitants). Results: The test's acceptance rate among the 2119 participants between the ages of 45 and 75 years amounted to 13.0%. Fifteen percent of all the tests conducted showed a positive PSA result (≥ 4 ng/ml). Prostate carcinoma was histologically confirmed in 14 (0.66%) of the men, nine times in the early stage (T2) and five times in the clinical stage (T3),corresponding to an incidence of circa 650 cases per 100,000 men in the target age group. Conclusions: This newly developed PSA test system can enhance the acceptance rate and effectiveness of medical check-ups for prostate cancer, because it is easy-to-use, cost-effective and accurate (specificity 81.3%, sensitivity 91.1%). The test should be always conducted by an experienced physician. It is not a substitute for a regular physical examination (DRE, TRUS, biopsy...).
Similar content being viewed by others
References
Statistisches Bundesamt Wiesbaden. Gesundheitsbericht für Deutschland 1997, Metzler-Poeschel. Wiesbaden, 1998: 186–395.
Chan EC, Sulmasy DP.What should men know about prostatespecific antigen screening before giving informed consent? Am J Med 1998; 105: 266.
Luboldt HJ, Altwein JE, Bichler KH, Czaja D, Hüsing J, Fornara P, Jöckel KH, Lübben G, Schalkhäuser K, Weißbach L, Wirth M, Rübben H. Projektgruppe Früherkennung DGU-BDU-Arbeitskreis Labordiagnostik: Früherkennung des Prostatakarzinoms - Erste Ergebnisse einer prospektiven multizentrischen Studie in Deutschland. Urologe [A] 1999; 38: 114.
Schmid HP, Altwein JE, Faul P, Wirth M. Screening und Früherkennung des Prostatkarzinoms - zwischen Szylla und Charybdis. Dtsch Ärztebl 1999; 96: A 772.
Berg W, Linder C, Eschholz G, Link S, Schubert J. Possibility of improving the acceptance rate of early detection testing for prostate cancer with a one-step test for prostate-specific antigen in whole blood. Urol Int 1999; 63: 102.
Schulz M, Zagermann-Muncke P. Prostata. Sind Schnelltests schnell, zuverlässig und sinnvoll? Pharm Ztg 1999; 144: 48.
Thüringer Landesamt für Statistik, Erfurt 1999. Bevölkerung am 31.12.1998 nach Geschlecht, Altersgruppen sowie Altersund Geburtsjahren für die kreisfreie Stadt Jena.
Höltl W. Screening beim Prostatakarzinom. Onkologie 1998; 21: 521.
Maattanen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, Juusela H, Hakama M. European randomized study of prostate cancer screening: First-year results of the Finnish trial. Br J Cancer 1999; 79: 1210.
Rietbergen JBW, Hoedemaeker RF, Boeken Kruger AE, Kirkels WJ, Schröder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999; 161: 1192.
Meyer F, Moore L, Bairati I, Fradet Y. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol 1999; 161: 1189.
Martin E, Lujan M, Sanchez E, Herrero A, Paez A, Berenguer A. Final results of a screening campaign for prostate cancer. Eur Urol 1999; 35: 26.
Gustafsson O, Norming U, Almgard LE, Fredriksson A, Gustavson G, Harvig B, Nyman CR. Diagnostic methods in the detection of prostate cancer: A study of a randomly selected population of 2,400 men. J Urol 1992; 148: 1827.
Jordan TR, Price JH, King KA, Masyk T, Bedell AW. The validity ofmale patients' self-reports regarding prostate cancer screening. Prev Med 1999; 28: 297.
Polaschik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J Urol 1999; 162: 293.
Schröder FH, van der Cruisen-Koeter J, de Koning HJ, Vis AN, Haedemaeker RF, Krause R. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 306.
Wingo PA, Tong T, Bolden D. Cancer statistics 1995. Cancer J Clin 1995; 45: 8.
Krimmel L. Untersuchung zur Früherkennung des Prostatakarzinoms mittels PSA - Test als individuelle Gesundheitsleistung. Urologe [B] 1999; 39: 282.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berg, W., Linder, C., Eschholz, G. et al. Pilot study of the practical relevance of a one-step test for prostate-specific antigen in capillary blood to improve the acceptance rate in the early detection program of prostate carcinoma. Int Urol Nephrol 32, 381–388 (2001). https://doi.org/10.1023/A:1017569621165
Issue Date:
DOI: https://doi.org/10.1023/A:1017569621165